Lv01
0 积分 2026-07-23 加入
Four Decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)—Part II: Dose Individualization and Approvability Evidence
2小时前
已完结
Four decades of History & Evolution of Clinical Pharmacology at US Food and Drug Administration (FDA)– Part I: Product Quality
2小时前
已完结
Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
2小时前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
2小时前
已完结
Regulatory Case Studies Encountered by Project Toxicologists in Drug Development
15天前
已完结
Non-invasive tests: Establishing efficacy for metabolic dysfunction–associated steatohepatitis beyond the biopsy—Current perspectives from the Division of Hepatology and Nutrition, US Food and Drug Administration
15天前
已完结
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer
22天前
已完结
Molecularly Guided Therapy in Hepatobiliary Cancers
1个月前
已完结
Molecularly Guided Therapy in Hepatobiliary Cancers: Current Standards and Emerging Horizons
1个月前
已完结
Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial
1个月前
已完结
皖公网安备34019202002308
